caa a22 4500 606234594 CHVBK 20210128101238.0 cr unu---uuuuu 210128e20150701xx s 000 0 eng 10.1007/s11010-015-2397-z doi (NATIONALLICENCE)springer-10.1007/s11010-015-2397-z MiR-492 is functionally involved in Oxaliplatin resistance in colon cancer cells LS174T via its regulating the expression of CD147 [Elektronische Daten] [Lipan Peng, Huaqiang Zhu, Jinshen Wang, Haina Sui, Honglai Zhang, Changqing Jin, Leping Li, Tao Xu, Ruizheng Miao] Chemotherapy remains the core of anticancer treatment. However, despite the tremendous strides made in the development of targeted anticancer therapies, emergence of resistance to chemotherapeutic drugs is still a major obstacle in the successful management of resistant tumors. Therefore, profound investigation into the in-depth molecular mechanisms of drug resistance is essential and may hopefully translate into effective therapies that can flip the switch from drug resistance to susceptibility. To develop novel-targeted therapy holds promise for conquering chemotherapy resistance, one of the major hurdles in current colon cancer treatment. Previous studies indicate that CD147 is involved in the progression of chemotherapy resistance in breast cancer and ovarian cancer cells and its expression is negative regulated by miR-492 in muscles cells. In the present study, we found that lower level of miR-492 is accompanied with increased expression of CD147 in Oxaliplatin-resistant colon cancer cell line LS174T/L-OHP as compared with its parental cell line LS174T. Exogenous expression of miR-492 in LS174T/L-OHP could sensitize its reaction on the treatment of Oxaliplatin, which is coincided with its directly reducing the expression of CD147. Furthermore, we found that knockdown of CD147 in LS174T/L-OHP could also sensitize its reaction of the treatment with Oxaliplatin. Besides, intratumoral delivering of miR-492 could also restore Oxaliplatin treatment response in Oxaliplatin-resistant xenografts in vivo. These findings provide direct evidences that the miR-492/CD147 axis might play an essential role in the Oxaliplatin resistance of colon cancer cells, suggesting that the miR-492/CD147 signaling cohort could be served as a novel therapeutic target for the treatment of chemotherapy resistant in colon cancer. Springer Science+Business Media New York, 2015 MiR-492 nationallicence Oxaliplatin nationallicence LS174T nationallicence CD147 nationallicence Peng Lipan Department of Gastrointestinal Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, People's Republic of China aut Zhu Huaqiang Department of Breast Surgery, Qingdao municipal hospital, Qingdao, People's Republic of China aut Wang Jinshen Department of Gastrointestinal Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, People's Republic of China aut Sui Haina Department of Radiotherapy, Shandong Cancer Hospital, Jinan, People's Republic of China aut Zhang Honglai Department of Gastrointestinal Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, People's Republic of China aut Jin Changqing Department of Gastrointestinal Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, People's Republic of China aut Li Leping Department of Gastrointestinal Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, People's Republic of China aut Xu Tao Department of Gastrointestinal Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, People's Republic of China aut Miao Ruizheng Department of Gastrointestinal Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, People's Republic of China aut Molecular and Cellular Biochemistry Springer US; http://www.springer-ny.com 405/1-2(2015-07-01), 73-79 0300-8177 405:1-2<73 2015 405 11010 https://doi.org/10.1007/s11010-015-2397-z text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s11010-015-2397-z text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Peng Lipan Department of Gastrointestinal Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, People's Republic of China aut NATIONALLICENCE 700 1- Zhu Huaqiang Department of Breast Surgery, Qingdao municipal hospital, Qingdao, People's Republic of China aut NATIONALLICENCE 700 1- Wang Jinshen Department of Gastrointestinal Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, People's Republic of China aut NATIONALLICENCE 700 1- Sui Haina Department of Radiotherapy, Shandong Cancer Hospital, Jinan, People's Republic of China aut NATIONALLICENCE 700 1- Zhang Honglai Department of Gastrointestinal Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, People's Republic of China aut NATIONALLICENCE 700 1- Jin Changqing Department of Gastrointestinal Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, People's Republic of China aut NATIONALLICENCE 700 1- Li Leping Department of Gastrointestinal Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, People's Republic of China aut NATIONALLICENCE 700 1- Xu Tao Department of Gastrointestinal Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, People's Republic of China aut NATIONALLICENCE 700 1- Miao Ruizheng Department of Gastrointestinal Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, People's Republic of China aut NATIONALLICENCE 773 0- Molecular and Cellular Biochemistry Springer US; http://www.springer-ny.com 405/1-2(2015-07-01), 73-79 0300-8177 405:1-2<73 2015 405 11010